EZH2型
PRC2
前列腺癌
癌症研究
组蛋白甲基转移酶
生物
表观遗传学
抑制因子
辅活化剂
甲基转移酶
增强子
雄激素受体
癌症
转录因子
基因
遗传学
甲基化
作者
Kexin Xu,Zhenhua J. Wu,Anna C. Groner,Housheng Hansen He,Changmeng Cai,Rosina T. Lis,Xiaoqiu Wu,Edward C. Stack,Massimo Loda,Tao Liu,Han Xu,Laura Cato,James E. Thornton,Richard I. Gregory,Colm Morrissey,Robert L. Vessella,Rodolfo Montironi,Cristina Magi‐Galluzzi,Philip W. Kantoff,Steven P. Balk,X. Shirley Liu,Myles Brown
出处
期刊:Science
[American Association for the Advancement of Science (AAAS)]
日期:2012-12-14
卷期号:338 (6113): 1465-1469
被引量:779
标识
DOI:10.1126/science.1227604
摘要
Alternative Role for EZH2 Epigenetic regulators are implicated in cancer progression and proposed as therapeutic targets. Xu et al. (p. 1465 ; see the Perspective by Cavalli ) report that EZH2 (Enhancer of zeste homolog 2), a factor previously thought to exert its oncogenic function primarily as part of the polycomb repressive complex, acts through a distinct mechanism in cells of castration-resistant prostate cancer. Rather than exclusively silencing gene expression through histone methylation, EZH2 acts as a transcriptional coactivator. The activation function of EZH2 plays a critical role in the growth of castration-resistant prostate cancer cells, which could be relevant in future drug development.
科研通智能强力驱动
Strongly Powered by AbleSci AI